Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business

The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period

Drug major Dr Reddy's Laboratories Limited has reported a 22 per cent increase in profit before tax (PBT) at Rs 714.2 crore for the fourth quarter ended March 31, on the back of a greater contribution of revenues from the US and the European markets. 

The company has registered 10 per cent growth in revenues at Rs 4,431.8 crore for the quarter under review from Rs 4,016.6 crore in the corresponding quarter previous year.

For the full year 2019-20, Dr Reddy's PBT declined 20 per cent to Rs 1,803.2 crore from Rs 2,244.3 crore in the previous financial year. However,